You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
誤殺!港股生物技術股集體反彈
格隆匯12月16日丨昨日因“美國製裁”傳聞集體大跌的生物技術股今日集體反彈。其中,藥明生物漲11%,藥明康德漲超8%,泰格醫藥、昭衍新藥漲超7%,亞盛醫藥漲6%,歌禮制藥、錦欣生殖等漲超4%,君實生物漲超3%。此前英國《金融時報》援引知情人士稱,美國商務部、財政部本週四(12月16日)將把20多家中國公司列入實體清單上,其中包括一些涉及生物技術的公司。12月15日晚,美國財政部正式發佈制裁文件,其制裁對象為參與國際非法藥物貿易相關個人及公司,核心目的是整治美國十分嚴重的芬太尼等藥物濫用問題,被制裁的中國公司與上市CXO及生物醫藥創新公司並不相關。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.